Daewoong Pharmaceutical said it has officially launched Nabota, its botulinum toxin (BTX) strain, in the United States. The company received sales approval from the U.S. Food and Drug Administration for Nabota in February.
|Daewoong Pharmaceutical's botulinum toxin Nabota|
Evolus, Daewoong’s U.S. partner, will be in charge of sales and marketing of the product. Evolus plans to market the product under the name of Jeuveau, Daewoong said.
The company plans to present Jeuveau to over 3,000 U.S. medical workers Wednesday through its “Jeuveau Experience Treatment (JET)” program.
“The launch of Jeuveau in the U.S. is a grand feat not only for Daewoong but also for other Korean pharmaceutical companies,” said Park Sung-soo, head of Daewoong’s Nabota business division. “We are very pleased that Daewoong has entered the largest botulinum toxin market in the world.”
Despite the launch of Nabota, Daewoong still has some hurdles it needs to clear. For example, the company is still in a heated debate over the origin of the BTX with Medytox.
Most recently, the U.S. International Trade Commission (ITC) has ordered Daewoong to submit Nabota’s strain and other related documents and information to Medytox so that the latter can test Daewoong’s BTX strain.
The investigation comes after Allergan and Medytox submitted a complaint to the ITC, claiming that Daewoong developed the treatment using stolen manufacturing secrets and turncoat former employees.
According to Medytox, Daewoong had tried to keep Nabota strains and related documents from being included in the evidence list, which might affect the outcome of the trial before the ITC’s administrative ruling.
The ITC.’s decision is likely to come out no later than June next year, as the U.S. Customs Act mandates that all ICT procedures be finished within 15 months.
<© Korea Biomedical Review, All rights reserved.>